The goal in demanding the introduction of the mechanism was that multiple companies would immediately trigger independent reviews with US Government support, draw attention to problems in decision-making, essentially overwhelm the system, and force further reform discussions. None of this happened, the US Government quickly lost confidence in the industry, and the Australian Government more successfully leveraged the agreement outcome.
Why the failure of a hard-won process reveals so much about an intractable problem
January 16, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News

